Nayak TK - Search Results

1

Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy.

Waldhauer I, Gonzalez-Nicolini V, Freimoser-Grundschober A, Nayak TK, Fahrni L, Hosse RJ, Gerrits D, Geven EJW, Sam J, Lang S, Bommer E, Steinhart V, Husar E, Colombetti S, Van Puijenbroek E, Neubauer M, Cline JM, Garg PK, Dugan G, Cavallo F, Acuna G, Charo J, Teichgräber V, Evers S, Boerman OC, Bacac M, Moessner E, Umaña P, Klein C. Waldhauer I, et al. Among authors: nayak tk. MAbs. 2021 Jan-Dec;13(1):1913791. doi: 10.1080/19420862.2021.1913791. MAbs. 2021. PMID: 33974508 Free PMC article.

2

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.

Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, Lang S, Roemmele M, Hofer T, van Puijenbroek E, Wittig D, Moser S, Ast O, Brünker P, Gorr IH, Neumann S, de Vera Mudry MC, Hinton H, Crameri F, Saro J, Evers S, Gerdes C, Bacac M, van Dongen G, Moessner E, Umaña P. Klein C, et al. Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402X.2016.1277306. eCollection 2017. Oncoimmunology. 2017. PMID: 28405498 Free PMC article.

3

Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy.

Ribba B, Boetsch C, Nayak T, Grimm HP, Charo J, Evers S, Klein C, Tessier J, Charoin JE, Phipps A, Pisa P, Teichgräber V. Ribba B, et al. Clin Cancer Res. 2018 Jul 15;24(14):3325-3333. doi: 10.1158/1078-0432.CCR-17-2953. Epub 2018 Feb 20. Clin Cancer Res. 2018. PMID: 29463551

4

Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity.

Sam J, Colombetti S, Fauti T, Roller A, Biehl M, Fahrni L, Nicolini V, Perro M, Nayak T, Bommer E, Schoenle A, Karagianni M, Le Clech M, Steinhoff N, Klein C, Umaña P, Bacac M. Sam J, et al. Front Oncol. 2020 Nov 30;10:575737. doi: 10.3389/fonc.2020.575737. eCollection 2020. Front Oncol. 2020. PMID: 33330050 Free PMC article.

5

Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti-Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis.

Laverman P, van der Geest T, Terry SY, Gerrits D, Walgreen B, Helsen MM, Nayak TK, Freimoser-Grundschober A, Waldhauer I, Hosse RJ, Moessner E, Umana P, Klein C, Oyen WJ, Koenders MI, Boerman OC. Laverman P, et al. Among authors: nayak tk. J Nucl Med. 2015 May;56(5):778-83. doi: 10.2967/jnumed.114.152959. Epub 2015 Apr 9. J Nucl Med. 2015. PMID: 25858044 Free article.

6

Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of (18) F-FDG-PET and (18) F-FLT-PET.

Geven EJ, Evers S, Nayak TK, Bergström M, Su F, Gerrits D, Franssen GM, Boerman OC. Geven EJ, et al. Among authors: nayak tk. Contrast Media Mol Imaging. 2015 May-Jun;10(3):203-10. doi: 10.1002/cmmi.1619. Epub 2014 Sep 9. Contrast Media Mol Imaging. 2015. PMID: 25204436 Free article.

7

Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity.

Sam J, Colombetti S, Fauti T, Roller A, Biehl M, Fahrni L, Nicolini V, Perro M, Nayak T, Bommer E, Schoenle A, Karagianni M, Le Clech M, Steinhoff N, Klein C, Umaña P, Bacac M. Sam J, et al. Front Oncol. 2021 Feb 3;11:650149. doi: 10.3389/fonc.2021.650149. eCollection 2021. Front Oncol. 2021. PMID: 33614518 Free PMC article.

8

Liposomal Treatment of Experimental Arthritis Can Be Monitored Noninvasively with a Radiolabeled Anti-Fibroblast Activation Protein Antibody.

van der Geest T, Laverman P, Gerrits D, Walgreen B, Helsen MM, Klein C, Nayak TK, Storm G, Metselaar JM, Koenders MI, Boerman OC. van der Geest T, et al. Among authors: nayak tk. J Nucl Med. 2017 Jan;58(1):151-155. doi: 10.2967/jnumed.116.177931. Epub 2016 Aug 4. J Nucl Med. 2017. PMID: 27493266 Free article.

9

Monitoring Therapy Response of Experimental Arthritis with Radiolabeled Tracers Targeting Fibroblasts, Macrophages, or Integrin αvβ3.

Terry SY, Koenders MI, Franssen GM, Nayak TK, Freimoser-Grundschober A, Klein C, Oyen WJ, Boerman OC, Laverman P. Terry SY, et al. Among authors: nayak tk. J Nucl Med. 2016 Mar;57(3):467-72. doi: 10.2967/jnumed.115.162628. Epub 2015 Dec 3. J Nucl Med. 2016. PMID: 26635344 Free article.

10

Imaging fibroblast activation protein to monitor therapeutic effects of neutralizing interleukin-22 in collagen-induced arthritis.

van der Geest T, Roeleveld DM, Walgreen B, Helsen MM, Nayak TK, Klein C, Hegen M, Storm G, Metselaar JM, van den Berg WB, van der Kraan PM, Laverman P, Boerman OC, Koenders MI. van der Geest T, et al. Among authors: nayak tk. Rheumatology (Oxford). 2018 Apr 1;57(4):737-747. doi: 10.1093/rheumatology/kex456. Rheumatology (Oxford). 2018. PMID: 29361119

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

215 results

Search Page